Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide

被引：0
作者：
V. Guarnotta
G. Pizzolanti
A. Ciresi
C. Giordano
机构：
[1] University of Palermo,Biomedical Department of Internal and Specialist Medicine (DIBIMIS), Section of Diabetes, Endocrinology and Metabolism
来源：
Journal of Endocrinological Investigation | 2018年 / 41卷
关键词：
Pasireotide; Diabetes mellitus; Adipokines; Insulin sensitivity; Cushing’s disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1137 / 1147
页数：10
相关论文
共 225 条
  • [1] Graversen D(2002)Mortality in Cushing’s syndrome: a systematic review and meta-analysis Eur J Intern Med 23 278-282
  • [2] Vestergaard P(2008)Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery J Clin Endocrinol Metab 93 358-362
  • [3] Stochholm K(2009)Cushing’s disease: radiation therapy Pituitary 12 11-14
  • [4] Gravholt CH(2013)Clinical review: outcome of bilateral adrenalectomy in Cushing’s syndrome: a systematic review J Clin Endocrinol Metab 98 3939-3948
  • [5] Jørgensen JO(2015)Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline J Clin Endocrinol Metab 100 2807-2831
  • [6] Patil CG(2009)The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery J Clin Endocrinol Metab 94 223-230
  • [7] Prevedello DM(2009)Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial J Clin Endocrinol Metab 94 115-122
  • [8] Lad SP(2012)A 12-month phase 3 study of pasireotide in Cushing’s disease N Engl J Med 366 914-924
  • [9] Vance ML(2015)Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial Pituitary 18 604-612
  • [10] Thorner MO(2017)Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease Endocrine 48 290-298
12345678910